CN110151595A - The high efficiency composition system for preventing and treating striae of pregnancy and its application in cosmetics - Google Patents
The high efficiency composition system for preventing and treating striae of pregnancy and its application in cosmetics Download PDFInfo
- Publication number
- CN110151595A CN110151595A CN201910552421.8A CN201910552421A CN110151595A CN 110151595 A CN110151595 A CN 110151595A CN 201910552421 A CN201910552421 A CN 201910552421A CN 110151595 A CN110151595 A CN 110151595A
- Authority
- CN
- China
- Prior art keywords
- pregnancy
- striae
- cosmetics
- high efficiency
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to a kind of high efficiency composition system for preventing and treating striae of pregnancy and its applications in cosmetics, the compound system is by micromolecule hyaluronic acid sodium, chondroitin sulfate, fibrin peptide composition, amino acid group, ascorbic acid derivates, elastatinal, fibroblast promotor, moisture-regulating agent and matrix composition, based on the generation pathology of striae of pregnancy, from the maintenance of dermal matrix environment, the inhibition or alleviation of pathology, the nourishing and maintenance of skin, striae of pregnancy is effectively prevented in all directions, in addition, present invention could apply to lotions, cream, in the various skin care item such as gel, it is safe and non-stimulating, it is suitable for pregnant woman's product.
Description
Technical field
The invention belongs to beauty and health care fields, are related to striae of pregnancy Prevention Technique, especially prevent and treat the high efficiency composition of striae of pregnancy
System and its application in cosmetics.
Background technique
During gestation, the secretion level of internal adrenal gland glucocorticoid is begun to ramp up parent from second and third month, and the 6th
Reach within a month or so peak value, gives a birth latter to two weeks and restore normal.Adrenal gland glucocorticoid has the function of adjusting metabolism, promote
The decomposition of the outer protein of liver, and inhibit the synthesis of the outer protein of liver, promote lipolysis, promotes the heteroplasia of hepatic glycogen, make blood glucose
It increases, while inhibiting the utilization of glucose, so that the organs such as skin are suppressed the uptake and utilization of glucose.Adrenal gland sugar
Cortin can inhibit Fibroblast Function, and decompose elastic fibrin, make fibre modification.Under Electronic Speculum, occur in striae of pregnancy
Position, it is possible to find protein excessive decomposition, elastomer become fragile the thinning phenomenon of fracture, atrophoderma.
Skin tender, increase in uterus due to elastomer is denaturalized increase pregnant woman's abdominal skin tension, and skin is excessive
It upholds, fibrous fracture causes the generation of striae of pregnancy.So the key of prevention and treatment striae of pregnancy is to nourish skin, robust skin is fine
Structure is tieed up, enhances the elasticity and toughness of skin, to cope with the skin tension that the gestational period is gradually increased.
Protection striae of pregnancy product currently on the market has very much, mostly repairs elastomer as target using nourishes rough skin, but neglect
The influence of the specific skin physiological environment of pregnant women's is omited, effect is less desirable.Based on this, it is necessary to for pregnant woman's
Specific skin environment has developed a kind of high efficiency composition system for preventing and treating striae of pregnancy.
Summary of the invention
It is an object of the invention to provide the high efficiency composition system of prevention and treatment striae of pregnancy in place of overcome the deficiencies in the prior art
And its application in cosmetics, the system by micromolecule hyaluronic acid sodium, chondroitin sulfate, fibrin peptide composition,
Amino acid group, ascorbic acid derivates, elastatinal, fibroblast promotor, moisture-regulating agent and matrix group
At, based on the generation pathology of striae of pregnancy, from the maintenance of dermal matrix environment, the inhibition of pathology or alleviation, the nourishing of skin and
Maintenance, effectively prevents striae of pregnancy in all directions, in addition, present invention could apply in the various skin care item such as lotion, cream, gel,
It is safe and non-stimulating, it is suitable for pregnant woman's product.
The present invention solves its technical problem and adopts the following technical solutions to achieve:
The high efficiency composition system and its application in cosmetics, the system for preventing and treating striae of pregnancy include micromolecule hyaluronic acid
Sodium, chondroitin sulfate, fibrin peptide composition, amino acid group, ascorbic acid derivates, elastatinal, at
Fibrocyte promotor, moisture-regulating agent and matrix, wherein
Micromolecule hyaluronic acid sodium 0.05-0.5%,
Chondroitin sulfate 0.05-1%,
Fibrin peptide composition 1-100ppm,
Amino acid group 0.1-20%,
Ascorbic acid derivates 0.1-3%,
Elastatinal 0.01-1%,
Fibroblast promotor 0.01-1%,
Moisture-regulating agent 0.1-0.5%,
Matrix adds to 100%.
Moreover, the molecular weight of the micromolecule hyaluronic acid sodium is less than 10KDa.
Moreover, in terms of 1-100ppm, fibrin peptide composition includes:
Hexapeptide -90.1-50ppm,
Palmityl tripeptides -10.1-20ppm,
Palmityl hexapeptide -121-40ppm.
Moreover, in terms of 100%, the amino acid group includes:
Glycine 14-16%,
Proline 8-10%,
Alanine 5-7%,
Two palmityl hydroxy-proline 33-35%,
Acetylglutamate 7-9%,
Lauroyl arginine 10-12%,
Aspartic acid 3-5%,
Serine 1-3%,
Lauroyl lysine 4-6%,
Valine 1-3%,
Leucine 1-3%,
Threonine 1-3%,
Phenylalanine 1-3%,
Isoleucine 0.1-2%.
Moreover, the ascorbic acid derivates are magnesium ascorbyl phosphate.
Moreover, the elastatinal is one of rutin, Hyperoside, hanfangchin A, baicalein.
Moreover, the fibroblast promotor is one kind of white snow tea extraction, Astragaloside IV.
Moreover, in terms of 0.1-0.5%, the moisture-regulating agent includes:
Sodium Hyaluronate 0.1-0.5%,
Dimethyl silane alcohol hyaluronic acid ester 0.03-0.06%.
The advantages and positive effects of the present invention are:
1, the cell in extracellular matrix and corium (fibroblast, histocyte and mast cell etc.) together constitutes
Dermal connective tissue.Wherein, matrix is that the macromoleculars such as protein and polysaccharide secreted by cell are interweaved the netted knot of composition
Structure, including collagen, non-collagen glycoprotein, glycosaminoglycan and proteoglycan, four major class of elastin.They are not only to tissue
Cell rise support, protection and trophism, but also with the proliferation of cell, differentiation, metabolism, identify, stick together and migrate etc. substantially
Vital movement is closely related.
Hyaluronic acid is exactly one kind of glycosaminoglycan, it is mainly generated by fibroblast, in aqueous solution in loose
Reticular structure can adjust the water balance of skin, elastic force and anti-shearing force can be provided for skin in conjunction with a large amount of water is kept, and
By combining other extracellular matrixs to maintain the integrality of skin.And adrenal gland glucocorticoid has inhibition fibroblasts to secrete saturating
The effect of bright matter acid, therefore hyaluronic acid must be added in pregnant woman's skin care item, to supplement the missing in skin.
The molecular weight of the Sodium Hyaluronate used in usual cosmetics is both greater than 1000KDa, and the barrier function of skin makes
It cannot absorb macromolecular, and the Sodium Hyaluronate of macromolecular, which can only form one layer in skin surface, has the guarantor for catching water water lock function
Cuticula.And the molecular weight of micromolecule hyaluronic acid sodium of the present invention is less than 10KDa, and it can be completely through skin, deep moisturizing,
The effect of really playing the hyaluronic acid lacked in supplement skin, effectively reparation skin.
2, chondroitin sulfate (CS) is one kind of proteoglycan, is present in extracellular matrix, surrounds around collagen, makes
Clostridiopetidase A cannot act on collagen, and the protective barrier being formed simultaneously resists the invasion of free radical, reduce the generation of inflammation.
The adrenal gland glucocorticoid level of trimester maternal can improve, and act on fibroblast, activate Collagenase, and CS can one
The effect for determining degree shielding clostridiopetidase A, protects collagen.
Meanwhile CS can effectively inhibit Transin-1 (matrix metalloproteinase-3, MMP-
3), the synthesis of Matrix Metalloproteinase-9 (MMP-9), to protect elastin laminin, collagen, fiber laminins etc. a variety of
Fibre structure GAP-associated protein GAP.
3, collagen and elastin laminin are the raw materials for synthesizing collagenous fibres and elastomer, so the supplement of GAP-associated protein GAP
It is the key factor for guaranteeing that fibre structure is steady.There are many products to mend protein hydrolysate as the raw material of azelon on the market
It fills, but the barrier function of skin greatly suppresses the absorption of water-soluble macromolecule, such as protein hydrolysate.And the present invention uses small point
Sub- polypeptide and amino acid have established that its is high-effect as replenishers, from accelerate the damage skin repair stimulating growth factor secretion,
Promote collagen synthesis, promote elastin laminin synthesis, amino acid supplementation several respects Cooperative Maintenance skin fiber mechanism.
(1) fibrin peptide composition of the present invention includes palmityl tripeptides -1, hexapeptide -9, palmityl hexapeptide -
12。
(a) palmityl tripeptides -1 are a kind of signal peptide, structure Pal-Glycine-Histidine-Lysine
(GHK).GHK is the segment in bone laminins, and bone laminins play the role of adjusting endothelial function in tissue repair.GHK
It is present in human body with plasmoid and is successively decreased with the age, 200ng/ml at 20 years old, and 80ng/ml was reduced at 60 years old.
GHK can stimulate fibroblasts to secrete vascular endothelial growth factor (VEGF) and basic fibroblast growth factor
(bFGF), to promote the synthesis of collagen, elastin laminin, accelerate the reparation of striae of pregnancy.
(b) hexapeptide -9 is a kind of signal peptide, and it is collagen egg that structure, which is Glycyl-Prolyl-Glutaminyl (GPQ),
White sequence fragment.Every collagen peptide chain is mainly made of the repetitive structure of G-X-Y, and wherein X, Y are other other than glycine
Amino acid, it is greatly proline that X, which has,.GPQ can promote skin corium collagen (collagen I and collagen III)
Synthesis, moreover it is possible to improve the adhesiveness between cell, reinforce the transmitting of intercellular exchange and substance, promote epidermis and corium
It repairs.
(c) palmityl hexapeptide -12 is also a kind of signal peptide, structure Pal-Valyl-Glycyl-Valyl-Alanyl-
Prolyl-Glycine (VGVAPG) is the sequence fragment of elastin laminin, can activate insulin-like growth factor receptor (IGF-
1) expression of elastin laminin, is raised.Although the weight ratio part only 2% of elastin laminin in the dermis, plays skin elasticity
Vital effect.
(2) amino acid group of the present invention and weight ratio are as follows: glycine 14-16%, proline 8-10%, alanine
5-7%, two palmityl hydroxy-proline 33-35%, acetylglutamate 7-9%, lauroyl arginine 10-12%, asparagus fern ammonia
Sour 3-5%, serine 1-3%, lauroyl lysine 4-6%, valine 1-3%, leucine 1-3%, threonine 1-3%, benzene
Alanine 1-3%, isoleucine 0.1-2%.The amino acid group is according to the amino acid sequence of collagen and elastin laminin, respectively
The transdermal capability and actual skin efficacy test of kind amino acid are as a result, the combination of amino acids obtained, can effectively supplement because on kidney
Gland glucocorticoid increases caused amino acid deletions.
4, ascorbic acid is antioxidant important in human body, play it is anti-oxidant, remove Free Radical while, with number
Kind enzyme has synergistic effect, including lysine and proline hydroxylase, and adrenal gland glucocorticoid can reduce lysine and proline
The activity of hydroxylase.Ascorbic acid is that both enzymes maintain active confactor, can alleviate adrenal gland sugar skin to a certain degree
The effect of quality.Proline and lysine are hydroxylated under the action of collagen proline hydroxylase and collagen lysyl hydroxylase respectively
Hydroxyproline and hydroxylysine are generated, wherein hydroxyproline accounts for about 9.4% in collagen, amino acid sequence, is to maintain collagen
Albumen triple helix stereochemical structure key substance, thus ascorbic acid plays the role of stable collagen.
But the inoxidizability of ascorbic acid is stronger, easily oxidation deterioration in vitro, so using its derivative --- it is anti-
Bad hematic acid phosphate magnesium.It has lipophilicity, is easy to be absorbed by the skin, stable structure, when through after epidermis, in the work of phosphatase
With lower dephosphorylation, it is converted into ascorbic acid.
5, the fracture of elastomer be cause the immediate cause of striae of pregnancy, thus if there is can inhibit elastin laminin decompose
Substance exists, can effective protection elastomer.Elastatinal of the present invention has rutin, Hyperoside, the Chinese
Root of fangji A prime, baicalein.
6, excessive adrenal gland sugar skin element can inhibit fibroblastic proliferation and its function, so can promote into fiber
Cell biological function slows down damage of the excessive adrenal gland glucocorticoid to skin at branch.Wherein, Bai Xuecha (thamnolia vermicularia) is extracted
Object can promote fibroblast proliferation, secrete hyaluronic acid, promote the expression of Type I collagen albumen and elastin laminin, inhibit elasticity
The expression of protease；Astragaloside IV promotes fibroblast proliferation, promotes Type I collagen albumen proliferation.
7, skin is easy to happen pathological reaction in the case where lacking moisture, and keeping the wet of skin is that maintenance skin is strong
The one of the prerequisite of health.Moisture-regulating agent of the present invention has Sodium Hyaluronate and dimethyl silane alcohol hyaluronic acid
Ester.Although the hyaluronic acid of macromolecule cannot be fully absorbed by skin, but still it is excellent moisturizer, it is anti-forms one layer of moisturizing
Cuticula cooperates the Sodium Hyaluronate of small-molecular-weight that can preferably play its efficiency；Dimethyl silane alcohol hyaluronic acid ester is one
The hyaluronic acid ester that kind is modified by silanol.Silicon is the important composition element of skin connective tissue, by with mucopolysaccharide and albumen
Polysaccharide combines, and with structural proteins cooperation, supports the reticular structure of skin corium, can further stable skin fiber structure.Due to silicon
With the high affinity of dermal tissue, it can promote group in combination and enter skin corium, there is certain absorbefacient effect.
8, gestational period glucocorticoid is horizontal increases, and causes the various morbid state of skin: (1) reduction of hyaluronic acid.(2)
The increased activity of Collagenase and elastoser.(3) collagen and elastin laminin breaks down into amino acids, and further divide
Solution changes saccharogenesis at 2-ketoacid, and shortage occurs in amino acid.(4) synthesis of collagen and elastin laminin is suppressed.(5) at fibre
The performance for tieing up the proliferation and its function of cell is suppressed.High efficiency composition system proposed by the present invention, for above-mentioned various skins
Morbid state solves one by one, the skin health of maintenance pregnant woman in all directions.If only receiving in terms of single or several respects solve
It imitates little.If only promoting the synthesis of collagen and elastin laminin, hyaluronic acid is supplemented not in time, can inhibit the money between cell
Source transmitting, can not be effectively synthesized firm fibre structure.If not adding effective protease inhibitors, even if collagen and bullet
The synthesis of property albumen is increased, and can also be decomposed by efficient protease.If supplementing amino acid not in time, even if various cells
It also can not synthetic proteins matter all in optimal state with relevant components.If not adding fibroblast promotor, without enough
Cell carry out protein synthesis.If only promoting elastin laminin synthesis, and ignore the collagen to play a supportive role, even if bullet
Property albumen safeguarded, still may be broken.To sum up, gravidic spy could be effectively only safeguarded based on the overall situation
Different skin.
Detailed description of the invention
Fig. 1 is hydroxyproline standard curve；
Fig. 2 is Collagenase blank assay result；
Fig. 3 is chondroitin sulfate to collagenase activity inhibition assay result；
Fig. 4 is fibroblastic cultivation effect experimental result；
Fig. 5 is the facilitation experimental result that fibrin polypeptide synthesizes collagen and elastin laminin；
Fig. 6 is the anti-striae of pregnancy clinic trial result of lotion.
Specific embodiment
With table and by specific embodiment, the invention will be further described with reference to the accompanying drawing, and following embodiment is
Descriptive, it is not restrictive, this does not limit the scope of protection of the present invention.
The high efficiency composition system of prevention and treatment striae of pregnancy of the present invention and its application in cosmetics, can be applied to cream
It is safe and non-stimulating in the various skin care item such as liquid, cream, gel, it is suitable for pregnant woman's product.It is provided in following Examples corresponding real
The preparation method and effect evaluation result of border application.
The high efficiency composition system and its application in cosmetics, the system for preventing and treating striae of pregnancy include micromolecule hyaluronic acid
Sodium, chondroitin sulfate, fibrin peptide composition, amino acid group, ascorbic acid derivates, elastatinal, at
Fibrocyte promotor, moisture-regulating agent and matrix, wherein
Micromolecule hyaluronic acid sodium 0.05-0.5%,
Chondroitin sulfate 0.05-1%,
Fibrin peptide composition 1-100ppm,
Amino acid group 0.1-20%,
Ascorbic acid derivates 0.1-3%,
Elastatinal 0.01-1%,
Fibroblast promotor 0.01-1%,
Moisture-regulating agent 0.1-0.5%,
Matrix adds to 100%.
Moreover, the molecular weight of the micromolecule hyaluronic acid sodium is less than 10KDa.
Moreover, in terms of 1-100ppm, fibrin peptide composition includes:
Hexapeptide -90.1-50ppm,
Palmityl tripeptides -10.1-20ppm,
Palmityl hexapeptide -121-40ppm.
Moreover, in terms of 100%, the amino acid group includes:
Glycine 14-16%,
Proline 8-10%,
Alanine 5-7%,
Two palmityl hydroxy-proline 33-35%,
Acetylglutamate 7-9%,
Lauroyl arginine 10-12%,
Aspartic acid 3-5%,
Serine 1-3%,
Lauroyl lysine 4-6%,
Valine 1-3%,
Leucine 1-3%,
Threonine 1-3%,
Phenylalanine 1-3%,
Isoleucine 0.1-2%.
Moreover, the ascorbic acid derivates are magnesium ascorbyl phosphate.
Moreover, the elastatinal is one of rutin, Hyperoside, hanfangchin A, baicalein.
Moreover, the fibroblast promotor is one kind of white snow tea extraction, Astragaloside IV.
Moreover, in terms of 0.1-0.5%, the moisture-regulating agent includes:
Sodium Hyaluronate 0.1-0.5%,
Dimethyl silane alcohol hyaluronic acid ester 0.03-0.06%.
Moreover, this has high efficiency composition system to be applied in the various skin care item such as lotion, cream, gel for preventing and treating gestation
Line.
Test method and data are as follows:
One, chondroitin sulfate is measured using hydroxyproline colorimetric method to the inhibiting effect of Collagenase.
(1) reagent configures:
1, (37 DEG C, PH=7.4, the CaCl containing 5mmol/mL of Tris-HCl buffer2)
Three (methylol) aminomethane 605.7mg, concentrated hydrochloric acid 0.33mL, anhydrous CaCl are added255.5mg, it is ultrapure water-soluble
Solution, is settled to 100mL.
2, hydroxyproline standard solution
200.0 bottom μ g/mL liquid: weighing 20.0mg hydroxyproline standard object, and ultrapure water dissolution is settled to 100mL.
Series standard solution: a certain amount of bottom liquid is taken to be diluted to 1.0,2.0,3.0,4.0,5.0,6.0,7.0,8.0 μ respectively
g/mL。
3, acetic acid-citric acid solution (PH=6.0)
Sodium acetate 5.70g, trisodium citrate 3.75g, citric acid 0.55g, isopropanol 38.5mL, ultrapure water dissolution, constant volume
To 100mL.
4, oxidant
The dissolution of 5mL ultrapure water is added in 0.35g oronain T, adds 20mL acetic acid-citric acid solution.
5, color developing agent
4mL70% perchloric acid and 6mL isopropanol is added in 1g paradime thylaminobenzaldehyde.
6, indicator (0.1% bromthymol blue)
100mg bromthymol blue is dissolved in 100mL20% ethanol solution.
7, collagenase solution
0.1mg/mL clostridiopetidase A Tris-HCl solution is prepared respectively.
8, chondroitin sulfate solution
It is configured to the ultra-pure water solution of 0.2,0.6,1.0,1.4,1.8,2.2mg/mL respectively.
(2) experimental procedure
1, hydroxyproline standard curve
Take the standard solution 1.0mL of 1.0,2.0,3.0,4.0,5.0,6.0,7.0,8.0 μ g/mL in 5mL colorimetric cylinder respectively
In, 2.0mL isopropanol is added, the oxidant of the above-mentioned configuration of 1.0mL shakes up, aoxidizes 5min at room temperature, and it is aobvious that 2.0mL is added later
Toner, 60 DEG C of heating water baths colour developing 20min, becomes blood red from golden yellow, is put into ice-water bath cooling 5min rapidly later, uses
Ultraviolet specrophotometer measures absorbance at 561nm.Draw the linear equation of concentration and absorbance.
2, blank assay
The collagen of 10mg is weighed in 10mL glass water-bath reaction kettle, 5.0mL0.1mg/mL collagenase solution is added
With 1.0mL ultrapure water.37 DEG C of water bath with thermostatic control, stir at low speed, each hour terminate one experiment, totally six, after rapidly from
The isolated supernatant of the heart.2.0mL concentrated hydrochloric acid, 110 DEG C of acidolysis of baking oven are added in hydrolysis pipe in accurate 2.0mL supernatant of drawing
20h is cooled to room temperature, and 1d bromthymol blue indicator is added, is titrated to solution with NaOH solution and becomes champac color.It is transferred to
In 25mL volumetric flask, ultrapure water constant volume.It takes the prepare liquid of 1.0mL in 5mL colorimetric cylinder, 2.0mL isopropanol is added, on 1.0mL
The oxidant for stating configuration shakes up, aoxidizes 5min at room temperature, later addition 2.0mL color developing agent, 60 DEG C of heating water baths colour developing 20min,
Blood red is become from golden yellow, cooling 5min is put into ice-water bath rapidly later, is measured at 561nm with ultraviolet specrophotometer
Absorbance.
3, chondroitin sulfate is tested
The collagen of 10mg is weighed in 10mL glass water-bath reaction kettle, 5.0mL0.1mg/mL collagenase solution is added
Proteolysis assay is carried out with 1.0mL chondroitin sulfate solution.It 37 DEG C of water bath with thermostatic control, stirs at low speed, Quick spin separates after 3 hours
To supernatant.The same blank assay of step later.
(3) experimental result
Fig. 1 is hydroxyproline standard curve, and Fig. 2 is blank assay as a result, as seen from Figure 3, chondroitin sulfate is to collagen egg
White enzyme has certain activity inhibition, can protect collagen.
Two, fibrin peptide composition, chondroitin sulfate and hydrocortisone are to fibroblastic proliferation and function
Play adjustment effect.
(1) preparation of culture medium
1, blank cultures: the DMEM culture medium of 10% fetal calf serum.
2, hydrocortisone culture medium: the DMEM culture medium of preparation hydrocortisone containing 15ppm, 10% fetal calf serum.
3, fibrin polypeptide culture medium: the preparation -95ppm containing hexapeptide, palmityl tripeptides -11ppm, palmityl hexapeptide -
The DMEM culture medium of 1220ppm, 10% fetal calf serum.
4, hydrocortisone and fibrin polypeptide culture medium: preparation hexapeptide containing 5ppm -9,1ppm palmityl tripeptides -1,
20ppm palmityl hexapeptide -12,0.2% chondroitin sulfate, 15ppm hydrocortisone, 10% fetal calf serum DMEM culture medium.
5, hydrocortisone, fibrin polypeptide and chondroitin sulfate culture medium: preparation hexapeptide containing 5ppm -9,1ppm palm
Acyl tripeptides -1,20ppm palmityl hexapeptide -12,0.2% chondroitin sulfate, 15ppm hydrocortisone, 10% fetal calf serum
DMEM culture medium.
(2) experimental procedure
1, contain 10% fetal calf serum DMEM culture medium, 37 DEG C, 5%CO2, cultivate people in relative saturation humidified incubator
Dermal fibroblast (HDF) is chosen 4-6 and is tested for the cell of well-grown logarithmic growth phase.
2,1 × 10 will be diluted to5/ mL fibroblast is inoculated in 96 orifice plates, every group of 6 multiple holes by every 100 μ L of hole.
After cell is completely adherent, it is separately added into culture medium 1,2,3,4, at 37 DEG C, 5%CO2After lower culture for 24 hours, 50 μ L MTT are added
Solution continues to cultivate 4h, and after the MTT that exhausts, 150 μ L dimethyl sulfoxides are added in every hole, vibrates and measures wavelength with microplate reader after 10min
Light absorption value at 490nm.
3, the HDF handled respectively with step 2 with five groups of culture mediums extracts total protein according to BCA kit specification and counts
Protein concentration is calculated, fibrin polypeptide group protein concentration is adjusted by standard of blank group protein concentration, prepares protein adhesive, respectively take 50
After μ g protein sample carries out SDS-PAGE electrophoretic separation, protein delivery to pvdf membrane is closed with skimmed milk power, is cultivated at 4 DEG C
Secondary antibody is added after washing for 24 hours, incubated at room temperature 1h is analyzed by chemiluminescence imaging system, omparison purpose albumen and internal reference
The relative ratio of albumen (GAPHD) band absorbance.
(3) experimental result
1, fibroblastic cultivation effect is shown in Fig. 4 and table 1.
The fibroblastic cultivation effect experimental result of table 1
2, the facilitation that fibrin polypeptide synthesizes collagen and elastin laminin
The ratio of destination protein in blank assay and internal reference albumen (GAPHD) band absorbance is set as radix, i.e.,
100%, experimental result is shown in Fig. 5 and table 2.
The facilitation experimental result that 2 fibrin polypeptide of table synthesizes collagen and elastin laminin
Three, lotion and normal individual trial result containing prevention and treatment striae of pregnancy high efficiency composition system
A phase: caprylic/capric triglyceride 7%, Sweet Almond Oil 3%, jojoba oil 1%, C14-22 alcohol 1.5%, C12-20
Alkyl glucoside 0.5%, stearine 0.5%, PEG-100 stearine 0.5%；
B phase: glycerol 5%, butanediol 3%, micromolecule hyaluronic acid sodium 0.2%, chondroitin sulfate 0.3%, hyaluronic acid
Sodium 0.1%, magnesium ascorbyl phosphate 0.5%, Phenoxyethanol 0.5%, methylhexyl glycerol 0.1%, distilled water 66.19%；
C phase: hexapeptide -95ppm, palmityl tripeptides -11ppm, palmityl hexapeptide -1220ppm, glycine 1.47%, dried meat ammonia
Sour 0.88%, alanine 0.58%, two palmityl hydroxy-prolines 3.39%, acetylglutamate 0.82%, lauroyl essence ammonia
Sour 1.08%, aspartic acid 0.36%, serine 0.23%, lauroyl lysine 0.53%, valine 0.17%, leucine
0.19%, threonine 0.13%, phenylalanine 0.12%, isoleucine 0.08%, dimethyl silane alcohol hyaluronic acid ester
0.05%, rutin 0.05%, white snow tea extraction 0.01%.
(1) making step:
(1) oily phase processor
A phase is accurately weighed, is added to 80 DEG C, stirs evenly, keeps the temperature 15min, it is spare.
(2) water phase is handled
Magnesium ascorbyl phosphate is accurately weighed, suitable distilled water is added, stirring at normal temperature dissolution is spare.It accurately weighs
Except magnesium ascorbyl phosphate, other B phase constituents of Phenoxyethanol, 80 DEG C are heated to, is stirred evenly, keeps the temperature 20min.
(3) it emulsifies
Water phase is added in ascorbic acid sulfuric ester magnesium solution and Phenoxyethanol, 80 DEG C stir evenly, and keep the temperature 1min.It opens equal
Matter is slowly added to oily phase, homogeneous 2min.
(4) cool down
After homogeneous, cool down under slow stirring, be down to 45 DEG C, C phase is added, stirs evenly, be down to 35 DEG C, stops stirring.
(2) teratogenesis risk assessment is tested:
Several only conceptive healthy female mices are chosen, are calculated as the pregnancy period the 0th day.At the pregnancy period the 5th day, fertilization mouse 24 is selected
Only, it is divided into two groups, blank group 12, normal diet, experimental group 12, from the pregnancy period the 6th day to the 19th day, experimental group weighed daily
Female mice weight, and three lotion of case study on implementation of feeding 0.5g/100g.Pregnancy period the 20th day, 12 were respectively selected from blank group and experimental group
Female mice is put to death, and uterus is taken out, and checks tire mouse.Test result is shown in Table 3.
3 lotion teratogenesis risk assessment test result of table
(3) irritation test:
The female volunteers for selecting 30 20-50 years old adult healthies clean its forearm song side, 3 are contained added with 0.025g
There is the spot tester of the lotion of high efficiency composition system and left forearm that an empty spot tester is pasted on subject with low sensitization adhesive tape is bent
Side is gently pressed with finger and is allowed to even application on skin, continues 48h.30min (after impression disappearance), sees after removal spot tester
Examine dermoreaction.Dermoreaction grade scale is shown in Table 4, and test result is that the dermoreaction of 30 volunteers is negative reaction.
4 lotion dermoreaction grade scale of table
(4) anti-striae of pregnancy clinical test:
21 puerperas are invited, are started since pregnancy third month in abdomen smearing three lotion of case study on implementation, daily morning and evening each one
It is secondary, until childbirth the latter moon, observes its abdominal pregnancy line situation, test result is shown in Table 5 and Fig. 6.
5 lotion of table uses anti-striae of pregnancy clinic trial result
As can be seen from the above results the normal primipara of figure, in addition to 5 extras occur without striae of pregnancy.It is normal for figure
Multipara, striae of pregnancy also without aggravate situation.
Four, the cream containing prevention and treatment striae of pregnancy high efficiency composition system
A phase: caprylic/capric triglyceride 5%, Sweet Almond Oil 3%, beeswax 1%, C18-22 alcohol 2%, Butyrospermum parkii fruit rouge
2%, C14-22 alcohol 1.5%, C12-20 alkyl glucoside 0.5%, stearine 0.5%, PEG-100 stearine
0.5%；
B phase: glycerol 5%, butanediol 3%, micromolecule hyaluronic acid sodium 0.2%, chondroitin sulfate 0.2%, hyaluronic acid
Sodium 0.1%, magnesium ascorbyl phosphate 0.2%, Phenoxyethanol 0.5%, methylhexyl glycerol 0.1%, water 69.61%；
C phase: hexapeptide -90.1ppm, palmityl tripeptides -10.5ppm, palmityl hexapeptide -125ppm, glycine 0.74%, dried meat
Propylhomoserin 0.44%, alanine 0.29%, two palmityl hydroxy-prolines 1.7%, acetylglutamate 0.41%, lauroyl essence ammonia
Sour 0.54%, aspartic acid 0.18%, serine 0.12%, lauroyl lysine 0.27%, valine 0.09%, leucine
0.10%, threonine 0.07%, phenylalanine 0.06%, isoleucine 0.04%, dimethyl silane alcohol hyaluronic acid ester
0.03%, Hyperoside 0.05%, Astragaloside IV 0.01%.
Making step:
(1) oily phase processor
A phase is accurately weighed, is added to 80 DEG C, stirs evenly, keeps the temperature 15min, it is spare.
(2) water phase is handled
Magnesium ascorbyl phosphate is accurately weighed, suitable distilled water is added, stirring at normal temperature dissolution is spare.It accurately weighs
Except magnesium ascorbyl phosphate, other B phase constituents of Phenoxyethanol, 80 DEG C are heated to, is stirred evenly, keeps the temperature 20min.
(3) it emulsifies
Water phase is added in ascorbic acid sulfuric ester magnesium solution and Phenoxyethanol, 80 DEG C stir evenly, and keep the temperature 1min.It opens equal
Matter is slowly added to oily phase, homogeneous 2min.
(4) low-temperature treatment
After homogeneous, cool down under slow stirring, be down to 45 DEG C, C phase is added, stirs evenly, be down to 35 DEG C, stops stirring.
Five, the gel containing prevention and treatment striae of pregnancy high efficiency composition system
A phase: glycerol 2%, butanediol 2%, micromolecule hyaluronic acid sodium 0.5%, chondroitin sulfate 1%, Sodium Hyaluronate
0.5%, magnesium ascorbyl phosphate 1%, acrylic acid (ester) class/C10-30 alkylol acrylamide acid esters cross-linked polymer 1%, benzene oxygen second
Alcohol 0.5%, methylhexyl glycerol 0.1%, water 70.68%；
B phase: aminomethyl propanol: 0.5%
C phase: hexapeptide -910ppm, palmityl tripeptides -15ppm, palmityl hexapeptide -1230ppm, glycine 2.94%, dried meat ammonia
Sour 1.76%, alanine 1.16%, two palmityl hydroxy-prolines 6.78%, acetylglutamate 1.64%, lauroyl essence ammonia
Sour 2.16%, aspartic acid 0.72%, serine 0.46%, lauroyl lysine 1.06%, valine 0.34%, leucine
0.38%, threonine 0.26%, phenylalanine 0.24%, isoleucine 0.16%, dimethyl silane alcohol hyaluronic acid ester
0.1%, rutin 0.1%, white snow tea extraction 0.02%.
Making step:
(1) it pre-processes
Magnesium ascorbyl phosphate is accurately weighed, suitable distilled water is added, stirring at normal temperature dissolution is spare.It accurately weighs
Acrylic acid (ester) class/C10-30 alkylol acrylamide acid esters cross-linked polymer is spread on distillation water surface, infiltrates it sufficiently under room temperature, standby
With.
(2) high-temperature process
The remaining B phase constituent in viscous solution after infiltration except magnesium ascorbyl phosphate, Phenoxyethanol is accurately weighed,
60 DEG C are heated to, is stirred evenly, 20min is kept the temperature.
(3) it neutralizes
Water phase is added in ascorbic acid sulfuric ester magnesium solution and Phenoxyethanol, 60 DEG C stir evenly, and keep the temperature 1min.It is accurate to claim
B phase is taken, is added dropwise and neutralizes.
(4) low-temperature treatment
Cool down under slow stirring, be down to 45 DEG C, C phase is added, stirs evenly, be down to 35 DEG C, stops stirring.
Although disclosing the embodiment of the present invention and attached drawing for the purpose of illustration, those skilled in the art can be managed
Solution: do not departing from the present invention and spirit and scope of the appended claims in, various substitutions, changes and modifications be all it is possible,
Therefore, the scope of the present invention is not limited to the embodiment and attached drawing disclosure of that.
Claims (8)
1. the high efficiency composition system for preventing and treating striae of pregnancy and its application in cosmetics, it is characterised in that: the system includes small point
Sub- Sodium Hyaluronate, chondroitin sulfate, fibrin peptide composition, amino acid group, ascorbic acid derivates, elastoser
Inhibitor, fibroblast promotor, moisture-regulating agent and matrix, wherein
Micromolecule hyaluronic acid sodium 0.05-0.5%,
Chondroitin sulfate 0.05-1%,
Fibrin peptide composition 1-100ppm,
Amino acid group 0.1-20%,
Ascorbic acid derivates 0.1-3%,
Elastatinal 0.01-1%,
Fibroblast promotor 0.01-1%,
Moisture-regulating agent 0.1-0.5%,
Matrix adds to 100%.
2. the high efficiency composition system of prevention and treatment striae of pregnancy according to claim 1 and its application in cosmetics, feature
Be: the molecular weight of the micromolecule hyaluronic acid sodium is less than 10KDa.
3. the high efficiency composition system of prevention and treatment striae of pregnancy according to claim 1 and its application in cosmetics, feature
Be: in terms of 1-100ppm, fibrin peptide composition includes:
- 9 0.1-50ppm of hexapeptide,
- 1 0.1-20ppm of palmityl tripeptides,
- 12 1-40ppm of palmityl hexapeptide.
4. the high efficiency composition system of prevention and treatment striae of pregnancy according to claim 1 and its application in cosmetics, feature
Be: in terms of 100%, the amino acid group includes:
Glycine 14-16%,
Proline 8-10%,
Alanine 5-7%,
Two palmityl hydroxy-proline 33-35%,
Acetylglutamate 7-9%,
Lauroyl arginine 10-12%,
Aspartic acid 3-5%,
Serine 1-3%,
Lauroyl lysine 4-6%,
Valine 1-3%,
Leucine 1-3%,
Threonine 1-3%,
Phenylalanine 1-3%,
Isoleucine 0.1-2%.
5. the high efficiency composition system of prevention and treatment striae of pregnancy according to claim 1 and its application in cosmetics, feature
Be: the ascorbic acid derivates are magnesium ascorbyl phosphate.
6. the high efficiency composition system of prevention and treatment striae of pregnancy according to claim 1 and its application in cosmetics, feature
Be: the elastatinal is one of rutin, Hyperoside, hanfangchin A, baicalein.
7. the high efficiency composition system of prevention and treatment striae of pregnancy according to claim 1 and its application in cosmetics, feature
Be: the fibroblast promotor is one kind of white snow tea extraction, Astragaloside IV.
8. the high efficiency composition system of prevention and treatment striae of pregnancy according to claim 1 and its application in cosmetics, feature
Be: in terms of 0.1-0.5%, the moisture-regulating agent includes:
Sodium Hyaluronate 0.1-0.5%,
Dimethyl silane alcohol hyaluronic acid ester 0.03-0.06%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910552421.8A CN110151595B (en) | 2019-06-25 | 2019-06-25 | Compound composition for preventing and treating stretch marks |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910552421.8A CN110151595B (en) | 2019-06-25 | 2019-06-25 | Compound composition for preventing and treating stretch marks |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110151595A true CN110151595A (en) | 2019-08-23 |
| CN110151595B CN110151595B (en) | 2022-02-11 |
Family
ID=67626827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910552421.8A Active CN110151595B (en) | 2019-06-25 | 2019-06-25 | Compound composition for preventing and treating stretch marks |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110151595B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113121705A (en) * | 2021-04-19 | 2021-07-16 | 成都英普博集生物科技有限公司 | Fusion protein for preparing short peptide mixture, target polypeptide, preparation method and application of short peptide mixture |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070118719A (en) * | 2006-06-13 | 2007-12-18 | 주식회사 씨에이팜 | Skin topical composition containing epidermal growth factor and fibroblast growth factor |
| US20110268759A1 (en) * | 2008-07-11 | 2011-11-03 | Laboratoires Expanscience | Novel anti-stretch mark active agent, and compositions containing same |
| US20140296155A1 (en) * | 2011-09-23 | 2014-10-02 | Amy Newburger | Anti-stretch mark skin cream and method for making and using thereof |
| CN106265310A (en) * | 2016-08-31 | 2017-01-04 | 天津天狮生物发展有限公司 | Prevention striae gravidarum compositions and striae gravidarum frost and preparation method thereof |
| CN107519036A (en) * | 2017-09-06 | 2017-12-29 | 深圳肽之妃科技有限公司 | A kind of striae of pregnancy spray containing polypeptide and preparation method thereof |
| CN108904320A (en) * | 2018-09-20 | 2018-11-30 | 深圳市维琪医药研发有限公司 | A kind of peptide composition of prevention and improvement striae of pregnancy |
-
2019
- 2019-06-25 CN CN201910552421.8A patent/CN110151595B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070118719A (en) * | 2006-06-13 | 2007-12-18 | 주식회사 씨에이팜 | Skin topical composition containing epidermal growth factor and fibroblast growth factor |
| US20110268759A1 (en) * | 2008-07-11 | 2011-11-03 | Laboratoires Expanscience | Novel anti-stretch mark active agent, and compositions containing same |
| US20140296155A1 (en) * | 2011-09-23 | 2014-10-02 | Amy Newburger | Anti-stretch mark skin cream and method for making and using thereof |
| CN106265310A (en) * | 2016-08-31 | 2017-01-04 | 天津天狮生物发展有限公司 | Prevention striae gravidarum compositions and striae gravidarum frost and preparation method thereof |
| CN107519036A (en) * | 2017-09-06 | 2017-12-29 | 深圳肽之妃科技有限公司 | A kind of striae of pregnancy spray containing polypeptide and preparation method thereof |
| CN108904320A (en) * | 2018-09-20 | 2018-11-30 | 深圳市维琪医药研发有限公司 | A kind of peptide composition of prevention and improvement striae of pregnancy |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113121705A (en) * | 2021-04-19 | 2021-07-16 | 成都英普博集生物科技有限公司 | Fusion protein for preparing short peptide mixture, target polypeptide, preparation method and application of short peptide mixture |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110151595B (en) | 2022-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11752168B2 (en) | Methods of using cosmetic compositions comprising exopolysaccharides derived from microbial mats | |
| US6620419B1 (en) | Cosmetic or dermopharmaceutical use of peptides for healing, hydrating and improving skin appearance during natural or induced ageing (heliodermia, pollution) | |
| JP4299463B2 (en) | Cosmetic treatment method for inhibiting skin aging action | |
| JP5010775B2 (en) | Use of ellagic acid and its derivatives in cosmetics and dermatology | |
| CN102762189B (en) | Cosmetic and/or pharmaceutical composition comprising an extract of carob as active agent for activating aquaporin expression | |
| US20090041875A1 (en) | Anti-wrinkle composition | |
| CA2229741A1 (en) | Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology | |
| CN108379110B (en) | Skin care composition, skin care cream and preparation method thereof | |
| KR101627562B1 (en) | Cosmetic Composition containing Human Adipocyte Conditioned Media Extract and Hyaluronic acid | |
| CN103385820A (en) | Repair eye cream | |
| CN110538093A (en) | polypeptide repair liquid and preparation method thereof | |
| CN101766550A (en) | Combination of monosaccharides and ascorbic acid and its use in cosmetic | |
| CN109833221A (en) | A kind of anti-ageing aging facial treatment milk of eye and preparation method thereof | |
| CN114588061A (en) | Anti-aging and wrinkle-removing composition, preparation method thereof and skin care product | |
| CN110151595A (en) | The high efficiency composition system for preventing and treating striae of pregnancy and its application in cosmetics | |
| CN106344435A (en) | Skin protection cream capable of eliminating striae gravidarum | |
| Uldbjerg | Cervical connective tissue in relation to pregnancy, labour, and treatment with prostaglandin E2 | |
| EP2101879A2 (en) | Cosmetic composition for the treatment and/or prevention of skin stretch marks | |
| CN107496194A (en) | A kind of surfactant and preparation method thereof | |
| CN116966118A (en) | Composition containing rose extract and application thereof | |
| CN110339105A (en) | A kind of eye skin care composition and its application | |
| Robert et al. | Effect of L-fucose and fucose-rich polysaccharides on elastin biosynthesis, in vivo and in vitro | |
| CN114209607A (en) | Method and composition for applying dipalmitoyl hydroxyproline | |
| WO2013188774A2 (en) | Skin care formulations including octapeptide complexes and methods for their manufacture | |
| CN111568844A (en) | Anti-aging composition and cosmetic using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |